12/16
08:27 am
lpcn
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone [Yahoo! Finance]
Neutral
Report
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone [Yahoo! Finance]
12/16
08:00 am
lpcn
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone
Low
Report
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone
12/9
04:25 pm
lpcn
Lipocine (NASDAQ:LPCN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Lipocine (NASDAQ:LPCN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/25
01:53 pm
lpcn
Lipocine (NASDAQ:LPCN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Lipocine (NASDAQ:LPCN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/18
08:26 am
lpcn
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) [Yahoo! Finance]
Medium
Report
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) [Yahoo! Finance]
11/18
08:00 am
lpcn
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Medium
Report
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
11/13
08:11 am
lpcn
Lipocine (NASDAQ:LPCN) had its price target lowered by analysts at HC Wainwright from $8.00 to $7.00. They now have a "buy" rating on the stock.
Medium
Report
Lipocine (NASDAQ:LPCN) had its price target lowered by analysts at HC Wainwright from $8.00 to $7.00. They now have a "buy" rating on the stock.
11/12
01:27 pm
lpcn
Lipocine (NASDAQ:LPCN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Lipocine (NASDAQ:LPCN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/6
08:00 am
lpcn
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025
Low
Report
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025
11/4
08:00 am
lpcn
Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®
High
Report
Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®
9/30
08:00 am
lpcn
Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)
Low
Report
Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)